Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Crizotinib (Xalkori) for advanced ROS1 positive non-small cell lung cancer – first line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Non-small cell lung cancer is the most common type of lung cancer. It is often diagnosed late and is difficult to treat once it has spread to other parts of the body. Cancer cells usually have mutations (abnormal changes) in their DNA when compared to normal cells. ROS1 is a rare type of mutation found in a small number of lung cancers.
Crizotinib is a drug that is being given for the treatment of non-small cell lung cancer. The drug is given as a tablet that is taken twice a day. Some studies have suggested crizotinib may be useful as a treatment for people who have advanced non-small cell lung cancer with a ROS1 mutation. Studies are currently ongoing to see how well crizotinib works and how safe it is to use.
If crizotinib is licensed for use in the UK, it could be a new treatment option for patients with advanced non-small cell lung cancer, which may improve survival and cause fewer side effects than current treatments (usually chemotherapy). Indexing Status Subject indexing assigned by CRD MeSH Carcinoma, Non-Small-Cell Lung; Humans; Pyrazoles; Pyridines Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000824 Date abstract record published 22/06/2016 |